CENPF and prostate cancer: However, CENPF was reported to be overexpressed, drive tumorigenesis and/or associated with poor prognosis in several human malignancies, including breast cancer [40], prostate cancer [41–44], bladder cancer [45], gastric cancer [46], hepatocellular carcinoma [47–49], pancreatic carcinoma [50].